Ascendia

25 Year BadgeDrug Development & Delivery Celebrates 25 Years!

For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!

  MARKET NEWS

Lonza Adds Qurient's CDK7 Inhibitors to Dual-Payload ADC Technology Portfolio
Carterra, AstraZeneca Collaborate on Hardware and Software for AI-Driven Drug Discovery
CPHI Pharma Awards 2026 Spotlight Innovation Across Pharma Industry
Lonza, Onava Partner to Generate Experimental Data for AI-Driven Biologics Discovery
Thermo Fisher Expands Drug Development and Manufacturing Offerings at CPHI Milan 2026
Terumo Launches K-Pack Embrace Safety Needle for Automated Drug Co-packing

  EXPERT CONTENT & RESOURCES

Monoclonal vs Polyclonal Antibody Production

Monoclonal vs Polyclonal Antibody Production

Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.

John Jansen

Managing Fragmented Small-Molecule Supply Chains Through Strategic Secondary Bulk Packaging

As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

  COMPANY PROFILE

Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients.

Learn More

 

  WHITEPAPERS & WEBINARS

WHITEPAPER - Large-Scale LNP Process Conversions

WHITEPAPER - Large-Scale LNP Process Conversions

Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider

Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once …

WEBINAR - Challenges of Sustained Release Drug Delivery Devices

WEBINAR - Challenges of Sustained Release Drug Delivery Devices

Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and costly. Programs can stall due to material–drug compatibility issues, inconsistent release profiles, tooling-related variability, and …

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and commercial relevance leads to success in formulation development and drug product design.

In this whitepaper, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 21 – Transdermal/Topical Delivery
October 28 – Formulation Development
November 4 – Drug Delivery
November 11 – Parenteral Contract Manufacturing

To advertise in a future eNewsletter contact:

John Kiesewetter jkiesewetter@drug-dev.com
Amy Nicklaus anicklaus@drug-dev.com

Submit eNewsletter content:

Cindy Dubin cdubin@drug-dev.com
Ralph Vitaro rvitaro@drug-dev.com